Metastasis prevention: targeting causes and roots
- 26 March 2022
- journal article
- review article
- Published by Springer Nature in Clinical & Experimental Metastasis
- Vol. 39 (4) , 505-519
Abstract
The spread of tumor cells from the primary focus, metastasis, is the main cause of cancer mortality. Therefore, anticancer therapy should be focused on the prevention of metastatic disease. Key targets can be conditions in the primary tumor that are favorable for the appearance of metastatic cells and the first steps of the metastatic cascade. Here, we discuss different approaches for targeting metastasis causes (hypoxia, metabolism changes, and tumor microenvironment) and roots (angiogenesis, epithelial-mesenchymal transition, migration, and invasion). Also, we emphasize the challenges of the existing approaches for metastasis prevention and suggest opportunities to overcome them. In conclusion, we highlight the importance of clinical evaluation of the agents showing antimetastatic effects in vivo, especially in patients with early-stage cancers, the identification of metastatic seeds, and the development of therapeutics for their eradication.Keywords
Funding Information
- Russian Science Foundation (grant number 20-75-10060)
This publication has 174 references indexed in Scilit:
- Proteolysis during Tumor Cell Extravasation In Vitro: Metalloproteinase Involvement across Tumor Cell TypesPLOS ONE, 2013
- Intratumoral macrophages contribute to epithelial-mesenchymal transition in solid tumorsBMC Cancer, 2012
- Notch Inhibition as a Promising New Approach to Cancer Therapy2012
- Anti-VEGF and beyond: shaping a new generation of anti-angiogenic therapies for cancerDrug Discovery Today, 2011
- The principal urinary metabolite of allyl isothiocyanate, N-acetyl-S-(N-allylthiocarbamoyl)cysteine, inhibits the growth and muscle invasion of bladder cancerCarcinogenesis, 2011
- Tumor Metastasis: Molecular Insights and Evolving ParadigmsCell, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Development of Second-Generation VEGFR Tyrosine Kinase Inhibitors: Current StatusCurrent Oncology Reports, 2011
- Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)Annals of Oncology, 2010
- The molecular mechanisms of transition between mesenchymal and amoeboid invasiveness in tumor cellsCellular and Molecular Life Sciences, 2009